|
1
|
Ménard S, Tagliabue E, Campiglio M and
Pupa SM: Role of HER2 gene overexpression in breast carcinoma. J
Cell Physiol. 182:150–162. 2000.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Vallejos CS, Gómez HL, Cruz WR, Pinto JA,
Dyer RR, Velarde R, Suazo JF, Neciosup SP, León M, de la Cruz MA
and Vigil CE: Breast cancer classification according to
immunohistochemistry markers: Subtypes and association with
clinicopathologic variables in a peruvian hospital database. Clin
Breast Cancer. 10:294–300. 2010.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Yábar A, Meléndez R, Muñoz S, Deneo H,
Freire J, Domínguez V, Carrasco-Navarro RM, Diaz ME and
Velarde-López RE: Effect of Ki-67 assessment in the distribution of
breast cancer subtypes: Evaluation in a cohort of Latin American
patients. Mol Clin Oncol. 6:503–509. 2017.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Slamon DJ, Leyland-Jones B, Shak S, Fuchs
H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M,
et al: Use of chemotherapy plus a monoclonal antibody against HER2
for metastatic breast cancer that overexpresses HER2. N Engl J Med.
344:783–792. 2001.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Wu YT, Xu Z, Zhang K, Wu JS, Li X, Arshad
B, Li YC, Wang ZL, Li HY, Wu KN, et al: Efficacy and cardiac safety
of the concurrent use of trastuzumab and anthracycline-based
neoadjuvant chemotherapy for HER2-positive breast cancer: A
systematic review and meta-analysis. Ther Clin Risk Manag.
14:1789–1797. 2018.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Amiri-Kordestani L, Wedam S, Zhang L, Tang
S, Tilley A, Ibrahim A, Justice R, Pazdur R and Cortazar P: First
FDA approval of neoadjuvant therapy for breast cancer: Pertuzumab
for the treatment of patients with HER2-positive breast cancer.
Clin Cancer Res. 20:5359–5364. 2014.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Quartino AL, Li H, Jin JY, Wada DR,
Benyunes MC, McNally V, Viganò L, Nijem I, Lum BL and Garg A:
Pharmacokinetic and exposure-response analyses of pertuzumab in
combination with trastuzumab and docetaxel during neoadjuvant
treatment of HER2+ early breast cancer. Cancer Chemother
Pharmacol. 79:353–361. 2017.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Chen S, Liang Y, Feng Z and Wang M:
Efficacy and safety of HER2 inhibitors in combination with or
without pertuzumab for HER2-positive breast cancer: A systematic
review and meta-analysis. BMC Cancer. 19(973)2019.PubMed/NCBI View Article : Google Scholar
|
|
9
|
van Ramshorst MS, van Werkhoven E, Honkoop
AH, Dezentjé VO, Oving IM, Mandjes IA, Kemper I, Smorenburg CH,
Stouthard JM, Linn SC, et al: Toxicity of dual HER2-blockade with
pertuzumab added to anthracycline versus non-anthracycline
containing chemotherapy as neoadjuvant treatment in HER2-positive
breast cancer: The TRAIN-2 study. Breast. 29:153–159.
2016.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Attard CL, Pepper AN, Brown ST, Thompson
MF, Thuresson PO, Yunger S, Dent S, Paterson AH and Wells GA:
Cost-effectiveness analysis of neoadjuvant pertuzumab and
trastuzumab therapy for locally advanced, inflammatory, or early
HER2-positive breast cancer in Canada. J Med Econ. 18:173–188.
2015.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Krasniqi E, Pizzuti L, Barchiesi G, Sergi
D, Carpano S, Botti C, Kayal R, Sanguineti G, Marchetti P,
Botticelli A, et al: Impact of BMI on HER2+ metastatic
breast cancer patients treated with pertuzumab and/or trastuzumab
emtansine. Real-world evidence. J Cell Physiol. 235:7900–7910.
2020.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Matthews CM, Nymberg K, Berger M, Vargo
CA, Dempsey J, Li J, Ramaswamy B, Reinbolt R, Sardesai S,
Wesolowski R, et al: Pathological complete response rates with
pertuzumab-based neoadjuvant chemotherapy in breast cancer: A
single-center experience. J Oncol Pharm Pract. 26:572–579.
2020.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Rahardja S, Tan RYC, Sultana R, Leong FL
and Lim EH: Efficacy, patterns of use and cost of Pertuzumab in the
treatment of HER2+ metastatic breast cancer in
Singapore: The National cancer centre Singapore experience. World J
Clin Oncol. 11:143–151. 2020.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Booth CM, Karim S and Mackillop WJ:
Real-world data: Towards achieving the achievable in cancer care.
Nat Rev Clin Oncol. 16:312–325. 2019.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Wolff AC, Hammond ME, Hicks DG, Dowsett M,
McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M,
Fitzgibbons P, et al: Recommendations for human epidermal growth
factor receptor 2 testing in breast cancer: American society of
clinical oncology/college of American pathologists clinical
practice guideline update. J Clin Oncol. 31:3997–4013.
2013.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Food and Drug Administration: Pathological
Complete Response in Neoadjuvant Treatment of High-Risk Early-Stage
Breast Cancer: Use as an Endpoint to Support Accelerated Approval;
Guidance for Industry; Availability. https://www.federalregister.gov/documents/2014/10/07/2014-23845/pathological-complete-response-in-neoadjuvant-treatment-of-high-risk-early-stage-breast-cancer-use.
Accessed August 26, 2021.
|
|
17
|
National Cancer Institute: Common
Terminology Criteria for Adverse Events (CTCAE), v5.0, 2017.
|
|
18
|
Khozin S, Blumenthal GM and Pazdur R:
Real-world data for clinical evidence generation in Oncology. J
Natl Cancer Inst. 109(djx187)2017.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Gianni L, Pienkowski T, Im YH, Roman L,
Tseng LM, Liu MC, Lluch A, Staroslawska E, de la Haba-Rodriguez J,
Im SA, et al: Efficacy and safety of neoadjuvant pertuzumab and
trastuzumab in women with locally advanced, inflammatory, or early
HER2-positive breast cancer (NeoSphere): A randomised multicentre,
open-label, phase 2 trial. Lancet Oncol. 13:25–32. 2012.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Schneeweiss A, Chia S, Hickish T, Harvey
V, Eniu A, Hegg R, Tausch C, Seo JH, Tsai YF, Ratnayake J, et al:
Pertuzumab plus trastuzumab in combination with standard
neoadjuvant anthracycline-containing and anthracycline-free
chemotherapy regimens in patients with HER2-positive early breast
cancer: A randomized phase II cardiac safety study (TRYPHAENA). Ann
Oncol. 24:2278–2284. 2013.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Tiwari SR, Mishra P, Raska P, Calhoun B,
Abraham J, Moore H, Budd GT, Fanning A, Valente S, Stewart R, et
al: Retrospective study of the efficacy and safety of neoadjuvant
docetaxel, carboplatin, trastuzumab/pertuzumab (TCH-P) in
nonmetastatic HER2-positive breast cancer. Breast Cancer Res Treat.
158:189–193. 2016.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Spring L, Niemierko A, Haddad S, Yuen M,
Comander A, Reynolds K, Shin J, Bahn A, Brachtel E, Specht M, et
al: Effectiveness and tolerability of neoadjuvant
pertuzumab-containing regimens for HER2-positive localized breast
cancer. Breast Cancer Res Treat. 172:733–740. 2018.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Fasching PA, Hartkopf AD, Gass P, Häberle
L, Akpolat-Basci L, Hein A, Volz B, Taran FA, Nabieva N, Pott B, et
al: Efficacy of neoadjuvant pertuzumab in addition to chemotherapy
and trastuzumab in routine clinical treatment of patients with
primary breast cancer: A multicentric analysis. Breast Cancer Res
Treat. 173:319–328. 2019.PubMed/NCBI View Article : Google Scholar
|
|
24
|
van Ramshorst MS, van der Voort A, van
Werkhoven ED, Mandjes IA, Kemper I, Dezentjé VO, Oving IM, Honkoop
AH, Tick LW, van de Wouw AJ, et al: Neoadjuvant chemotherapy with
or without anthracyclines in the presence of dual HER2 blockade for
HER2-positive breast cancer (TRAIN-2): A multicentre, open-label,
randomised, phase 3 trial. Lancet Oncol. 19:1630–1640.
2018.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Masuda N, Ohtani S, Takano T, Inoue K,
Suzuki E, Nakamura R, Bando H, Ito Y, Ishida K, Yamanaka T, et al:
A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel
+ carboplatin + trastuzumab + pertuzumab (TCbHP), TCbHP followed by
trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in
HER2-positive primary breast cancer. Breast Cancer Res Treat.
180:135–146. 2020.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Schneeweiss A, Chia S, Hickish T, Harvey
V, Eniu A, Waldron-Lynch M, Eng-Wong J, Kirk S and Cortés J:
Long-term efficacy analysis of the randomised, phase II TRYPHAENA
cardiac safety study: Evaluating pertuzumab and trastuzumab plus
standard neoadjuvant anthracycline-containing and
anthracycline-free chemotherapy regimens in patients with
HER2-positive early breast cancer. Eur J Cancer. 89:27–35.
2018.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Hussain N, Said ASA and Khan Z: Safety
assessment of neoadjuvant pertuzumab combined with trastuzumab in
nonmetastatic HER2-positive breast cancer in postmenopausal elderly
women of South Asia. Int J Breast Cancer.
2018(6106041)2018.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Gavilá J, Oliveira M, Pascual T,
Perez-Garcia J, Gonzàlez X, Canes J, Paré L, Calvo I, Ciruelos E,
Muñoz M, et al: Safety, activity, and molecular heterogeneity
following neoadjuvant non-pegylated liposomal doxorubicin,
paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast
cancer (Opti-HER HEART): An open-label, single-group, multicenter,
phase 2 trial. BMC Med. 17(8)2019.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Beitsch P, Whitworth P, Baron P, Rotkis
MC, Mislowsky AM, Richards PD, Murray MK, Pellicane JV, Dul CL,
Nash CH, et al: Pertuzumab/trastuzumab/CT versus trastuzumab/CT
therapy for HER2+ breast cancer: Results from the
prospective neoadjuvant breast registry symphony trial (NBRST). Ann
Surg Oncol. 24:2539–2546. 2017.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Swain SM, Ewer MS, Viale G, Delaloge S,
Ferrero JM, Verrill M, Colomer R, Vieira C, Werner TL, Douthwaite
H, et al: Pertuzumab, trastuzumab, and standard anthracycline- and
taxane-based chemotherapy for the neoadjuvant treatment of patients
with HER2-positive localized breast cancer (BERENICE): A phase II,
open-label, multicenter, multinational cardiac safety study. Ann
Oncol. 29:646–653. 2018.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Garrison LP Jr, Babigumira J, Tournier C,
Goertz HP, Lubinga SJ and Perez EA: Cost-effectiveness analysis of
pertuzumab with trastuzumab and chemotherapy compared to
trastuzumab and chemotherapy in the adjuvant treatment of
HER2-positive breast cancer in the United States. Value Health.
22:408–415. 2019.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Carvalho AC, Vasconcelos VCA and Sasse AD:
Abstract P4-12-06: Cost-effectiveness analysis of pertuzumab plus
trastuzumab for advanced HER2-positive breast cancer in Brazil: A
public health system perspective. Cancer Res. 78 (Suppl
4)(P4-12-06)2018.
|
